HAIR LOSS PREVENTION

Abstract: Compositions to prevent or reduce hair loss, allowing the body to maintain normal, healthy hair growth, comprising a penetration enhancer together with a testosterone blocker or a vascular enhancer, or both.

Description: Hair Loss Prevention ' By . Roy 'Knowles, M.D. BACKGROUND My invention relates to preparations useful for maintaining normal, healthy hair bulb function, for preventing hair loss, and for medically treating androgenic alopecia and like der atological diseases. I will first review pertinent hair biology, then discuss prior art teachings in the field, and then describe my invention. Hair Biology Hair bulbs are responsible for normal, healthy hair growth and retention. Hair bulbs are located in the skin, about 3/16 of an inch below the skin surface. They are located just above the fatty layer at the very lower most position of the skin. The ' majority of facial and body hair growth is stimulated by androgens . However, the growth of scalp hair has been shown, in genetically programmed individuals, to be inhibited by 5α-dihydrotestosterone ("DHT") in individuals who enhibit a hereditary pre-disposition to baldness. Ebling, Dermatol. Clin. S. 467 (1987); Lucky, 4 Biochem. Soc. Transc. 597 (1988); Brodland et al . , 47 Cutis 173 (1991). DHT is produced by reducing testosterone with a 5α-reductase enzyme. The phenotypic expression of baldness does not occur in the absence of testosterone. 7Androgenic alopecia or common baldness represents 99 percent of all cases of hair loss. Broadland, id. The mechanism through which androgens regulate the biology of hair is by modulating the hair growth cycle. Ebling, 4 Biochem. Soc. Trans. 597; Bergfield et al . , 5 Dermatol. Clin. 491. The effect of DHT on hair growth appears to be related to local rather than systemic levels of the hormone. This is because the capacity of scalp skin from balding individuals to convert testosterone ("T") to DHT is greater than that observed in the scalp of non-balding individuals. Lucky, supra; Schweikert et al., 38 J. Clin. Endocrinol. Metab. 811. To prevent hair loss, maintain the health of hair bulbs, or to treat baldness, several compositions are known in the art. We discuss them now. Hair Loss Prevention Hair loss prevention preparations are known in the art. These include natural product preparations, biological products, vascular toners and testosterone blockers . Several prior art compositions are discussed in the accompanying Petition To Make Special and its accompanying references, the contents of which are incorporated herein by reference. Natural Products . Several inventors disclose natural compositions. Casero, United States Letter Patent No. 5,340,579, discloses a composition comprising (a) mucopolysaccharides, (b) human umbilical cord extract, (c) tetrahydrofurfuryl nicotinate, and (d) pharmaceutically and cosmetically acceptable excipients. Buck, United States Letter Patent No. 5,512,275 and 5,609,858, discloses a formulation for the treatment of androgenic alopecia, comprising liquor carbonis detergens in combination with spirits of camphor, castor oil, isopropyl alcohol. Chizick et al., United States Letter Patent No. 5 ' , 972,345, discloses a combination of saw palmetto extract, African pygeum extract, and stinging nettle extract. Biological Products. Hoke, United States Letter Patent No. 5,994,319, discloses using genetic material as a anti alopecia therapeutic. Hoke proposes using anti-sense oligonucleotides targeting 5-α reductases in conjunction with other hair growth enhancers. Tien, United States Letter Patent No. 5,574,011, discloses the use of a class of HRH analogs for treating male pattern baldness. Messenger, United States Letter Patent No. 6,020,327, discloses administering aromatase inhibitors to treat hair loss. Liao et al., United States Letter Patent No. 5,422,371 and 5,605,929, discloses a class of anti-androgenic compounds. Vascular Toners. Several organic chemicals are known to affect, the hair growth and hair retention cycle. These include minoxidil. I refer to minoxidil and similar kinds of compounds as "vascular toners," because they are believed to be effective due to their impact on local blood circulation. Minoxidil has been shown to stimulate hair growth or inhibit the loss of hair in a number of patients beginning to develop androgenic alopecia. Minoxidil is the generic name for 6- (1-piperidinyl) -2, 4-pyrimidinediamaine 3-oxide. Its preparation is disclosed in Anthony, W.C. et al . , United States Letters Patent No. 3,382,247 (1968); McCall, J.M., et al., 40 J. Organic Che . 3304 (1975); Gorecki, D.K.J., 17 Analytical Profiles of Drug Substances 185 (Academic Press, New York 1988) . It is more soluble (by weight minoxidil / ' volume of solvent) in non-polar solvents than polar ones (75 mg/ml' in propylene glycol; 44 g/ml in methanol; 6.5 in dimethyl sulfoxide; 2.2 mg/ml water) . Minoxidil is medically classified as an anti- hypertensive. It affects heart rate and rhythm. It has thus been used in an oral formulation as a cardiac drug. Andersson, 0., 205 Acta Med. Scand. 213 (1979); Moser, M., 26 Advan. Cardiol. 38 (1979) . Over dosage may create cardiac arrhythmias or other adverse side effects. See e.g., Carlson, E.S., 39 Toxicol. Applied Pharmacol. 1 (1977). Minoxidil is also medically classified as an anti- alopecia agent. Its efficacy in treating early male pattern baldness has been described in numerous published articles. E. g. , Olsen, E.A. et al . , 13 J. Am. Acad. Dermatol. 185 (1985); Novak, E., 24 Int. J. Dermatol. 82 (1982). Its limited percutaneous absorption and secretion is described in Franz, J.T., 121 Arch. Dermatol. 203 (1985). The mechanism by which minoxidil alters the hair growth cycle is uncertain. It is thought to act by increasing vascular circulation to the hair follicle. It is known that minoxidil effectiveness is more pronounced in scalp areas which are more vascular. Topical minoxidil is know to have certain shortcomings. It is effective in only about eight percent of adult male users. It produces "lanugo, " or baby-type, hair which is relatively thin. Further, and perhaps most significantly, after approximately 30 months of continuous use, minoxidil shows a sharp drop in effectiveness. After about thirty months of use, about half of the new hair growth falls out. Thus, while the user has somewhat more hair than originally, the user has less hair than originally seen. Testosterone Inhibitors. Inhibitors of steroid metabolism, particularly those that inhibit the conversion of testosterone to dihydro testosterone, have shown effects on hair cycles, including inhibition of hair loss. One class of enzymes targeted by these inhibitors are the steroid 5-α reductases . Certain 5α-reductase inhibitors have been shown to inhibit hair loss. For example, stump-tail macaque monkeys treated with the 5α-reductase inhibitor 17b-N,N, - dimethylcarbamoyl- -methyl- 4-aza- 5a-androstan- 3-one undergo significantly less age related hair loss than untreated monkeys. Ritt aster et al., 65 J. Clin/ Endocrinol. Metab. 188 (1987) . Similarly, finasteride, a 5α- reductase inhibitor, miniaturizes scalp hair follicles, reversing the balding process. "Merck's Propecia Shows Promise In Hair Loss," Marketletter (Mar. 31, 1997) . These inhibitors are thought to work by inhibiting the reduction of testosterone to DHT, as DHT is considered to be the more active form. The use of a combination of finasteride and minoxidil demonstrated that, in combination, these two drugs increased the rate of hair growth when compared to either compound administered alone. Diani, 74 J. Clin. Endocrinol. Metabol. 345. Minoxidil used in conjunction with effectors of steroid metabolism, leads to enhanced hair growth and decreased rates of hair loss. Testosterone blockers are known in the art (I use the term "testosterone blocker" to denote a competitive antiandrogen which inhibits the binding of testosterone or DHT onto its cell surface binding site, rather than a compound which is used to inhibit the reduction of testosterone into DHT.). Also known is their use systemically (orally or intravenously) . As systemic therapeutics, they are known in the art as having a key shortfall: their long term efficacy is compromised by their blocking of the androgenic feedback inhibition of gonadotropin secretion. This interference results in elevated gonadotropin secretion, which in turn increases testicular secretion of testosterone. The higher level of testosterone eventually overcomes the action of the antiandrogen. Liao, supra, at col. 3, lines 16-31. Thus, what is needed in the art is a safe and effective way to maintain both the healthy function of hair bulbs, and the health of existing hair, that avoids the shortfalls seen in the prior art. SUMMARY I have invented a kind of hair loss prevention composition. My invention is a new combination of already known types of compounds . My invention can be used either cosmetically (to maintain healthy hair growth) or pharmaceutically (to treat a medical condition) . It can be made using components already known in the art, allowing one to enjoy the predictability of use available with these old compounds. My invention is flexible enough, however, to also allow one to substitute newly-discovered compounds substantially equivalent to the already known compounds. Thus, my invention can be adapted to allow the user to use the safest, most effective components then available. I have found that certain compounds have greatly improved effectiveness - achieving ten times the benefit, or an entire order of magnitude - if combined with a skin penetration enhancer. The penetration enhancer delivers these compounds to the hair bulb, where the compounds are most needed. I have thus found that testosterone blockers, if applied topically (rather than syste ically administered) , are effective in preventing hair loss, and if used in conjunction with a dermal penetration enhancer. Such topical use avoids precipitating the systemic increase in testosterone production seen with oral administration, by minimizing systemic interference with normal gonadotropin secretion. I have also found that vascular toners, if applied topically in conjunction with a dermal penetration enhancer, work much better. DETAILED DESCRIPTION My invention includes a skin penetration enhancer used together with a testosterone blocker or a vascular enhancer, or both. I first discuss each component individually, and then discuss the combinations of these components that I have found most acceptable. Penetration Enhancers You can use a variety of skin penetration enhancers to make compositions that work as I intend. Penetration enhancers and skin penetrating formulations are known in the art. These include the variety of formulations used from time to time for both psoriasis treatment pharmaceuticals, and psoriasis prevention nutritional supplements and cosmetics. The penetration enhancer (or penetration agent) should be accepted for human use by relevant government agencies. . Thus, dimethyl sulfoxide, while within the scope of the claims, is not a preferred penetration enhancer where that compound is not approved for human topical use. The penetration enhancer should not chemically react with any other ingredient to impair or alter the composition's stability and shelf life. Thus, one should examine the possible reactivity of a given penetration enhancer with a given testosterone blocker or vascular toner. The penetration agent should be cosmetically acceptable. Thus, while I have tested dimethyl acetate, I do not favor it. While it is within the scope of the claims, it is a weak penetration enhancer. Thus, one needs to use a lot of it. In these high amounts, it smells bad. In contrast, methyl acetate is odorless, and I have tested and found it acceptable. Several inventors disclose liposome technology to deliver cosmetic and dermatology materials. See, for example, Lishko et al., United States Letter Patent No. ■ 5,753,263, discloses using liposomes to selectively deliver a composition to hair follicles. Liposomes are made of fatty material, and are suitable for delivering homogenous types of materials. As such, it may be difficult for a liposome to in fact work with a combination of a polar compound (like a minoxidil vascular toner) and a non-polar compound (such as a progesterone testosterone blocker) . I thus do not consider liposome technology within the scope of the term "penetration enhancer" in this patent. Vascular Toners My invention works with a variety of vascular toners. One can make compositions within the scope of. my invention with minoxidil analogs or derivatives, or with other anti-alopecia agents, such as diphencyprone, which work in a similar way, by improving local blood flow to the affected hair bulbs. Because it has such a broad volume of use and scientific study, I prefer to use minoxidil. I thus use it as an example throughout this specification. A vascular toner, if used to maintain healthy function of hair bulbs, must be delivered to .the small blood vessels feeding the hair bulbs . I have thus found that the effectiveness of the vascular toner is greatly improved if it is topically applied along with a penetration enhancer. This allows the vascular toner to act locally. The vascular toner must be carefully titrated against the penetration enhancer. For example, for a given concentration of minoxidil, one needs to use the penetration enhancer in the appropriate concentration. If a given penetration enhancer is used in a too high concentration, the minoxidil may penetrate through the skin and reach the systemic blood circulation. It can there, if present in sufficient amount, cause side effects as seen by taking oral minoxidil. Thus, it is necessary to adjust the amounts of penetration enhancer and vascular toner, depending on the concentration and specific identity of the enhancer and the toner. Adding a penetration enhancer- to the vascular toner appears to fundamentally change the biological mechanism by which the vascular toner works. This is shown by the qualitatively different results seen between minoxidil and my compounds. The two products produce different types of hair, and for different time periods. Minoxidil without a penetration enhancer (as available in ROGAINE™ topical minoxidil U.S. P.) produces a different kind of hair than does minoxidil used with a penetration enhancer. It is known in the art that topical minoxidil without a penetration enhancer (as is commercially available in ROGAINE (TM) topical minoxidil U.S. P., commercially available from Pharmacia & Upjohn Inc., Bridgewater, New Jersey) results in thin, baby-like, temporary hair, called "lanugo" hair. I have found that my compounds, by contrast, result in good, coarse, "terminal" hair, hair which is normal, permanent adult hair. This indicates that minoxidil without and with penetration enhancer may act on different types of hair bulbs, or produce different responses from the same hair bulbs. Minoxidil without enhancer is only weakly soluble in polar solvents. See supra. It thus has difficulty diffusing to the deeply located hair bulbs (roots) which are located just above the deep fat layer. Minoxidil without enhancer may thus affect only hair bulbs located close to the skin surface, or located in a less fatty skin layer, or hair bulbs most sensitive to changes in blood flow. Alternatively, it may affect the same hair bulbs, but with such weak or attenuated effect that the hair bulbs produce a different type of hair. In contrast, my compounds produce normal, terminal hair. This indicates that my compounds act directly on the mature, adult hair bulbs responsible for terminal hair growth. Further, it is known in the art that minoxidil users experience a sudden drop in hai ' r thickness after about thirty months of usage. I thus have sought the time at which my compounds have a sudden drop in effectiveness. Surprisingly, I have found that my compounds apparently do not lose effectiveness at all, even after using them for substantially greater ' than thirty months. This confirms that while my compounds appear to simply restore or preserve normal hair bulb function, the prior art compositions do not restore normal hair bulb function, but actually provoke an abnormal function - the growth by an adult of baby like, temporary hair. That this function is abnormal is confirmed by its drop in effectiveness after thirty months; such a drop in efficacy indicates a "tolerance" acquired against the intervention, rather than the maintenance of a permanent, healthy state. This indicates that the physiological mechanisms and biomedical pathways of the two preparations are different. Minoxidil alone, in the concentrations typically used, may actually temporarily alter a normal adult body function (causing the adult body to temporarily produce infant hair) . In contrast, my invention simply maintains the normal function of the healthy adult body hair bulb, allowing it to continue to produce normal adult hair as long as the compound is used. I have also found that the effect of the formulations depends on location of administration. Using the specific formulations disclosed here, I have observed decreases in hair loss, and a consequent statistically significant increase in the amount of healthy mature hair, after 4.0 - 4.5 months on the frontal scalp. On the crown and back of the head, by contrast, I have observed statistically significant results after 4.5 - 5.0 months. The frontal scalp may react faster because it enjoys greater vascularization and blood flow than the other parts of the scalp. Testosterone Blocker My invention works with a variety of testosterone blockers. I prefer to use a blocker already approved for human use by the United States Food & Drug Administration, as these types of testosterone blockers, if used in pharmaceutical (as opposed to cosmetic) versions of my invention, do not need to undergo as lengthy and expensive a process to verify their safety and efficacy as used in pharmaceutical products. Examples include flutamide, cyproterone acetate, spironolactone, progesterone, or analogs or derivatives of any of these (e.g., 17-hydroxy-16- methylene-Δ 6 -progesterone, 17α-hydroxyprogesterone) . I have found several surprising things about testosterone blockers. First, they are not actually necessary for my invention to work; minoxidil alone is effective on 8% of patients, while the same amount of minoxidil administered with the proper amount of a penetration enhancer is effective on 35% of patients. Second, testosterone blockers added to such a mix are synergistically beneficial, increasing the efficacy from 35% to 85% of patients. One testosterone blockler is the anti alopecia compund cioteronel. Cioteronel is the common name for hexahydro-4- (5-methoxyheptyl) -2 (1H) -pentalenone. It is also known, or is commercially available, as X-ANDRON™, CPC-10997, CYOCTOL™, and EXANDRON™. It is a clear, colorless oil, soluble in lipid and relatively non-polar solvents. Its preparation is disclosed in Kasha, W.J., PCT Int'l Patent Application 83/04,019 (1983), 101 Chem. Abstr. 23037k (1984). Its use is disclosed in United States Letter Patent No. 4,689,345. Its inhibition of DHT binding in vitro i-s disclosed in Rec. Adv. Chemotherapy (Proc. 14 th Int'l Congr. Chemotherapy Antimicrob., Sect. 1) at 261-70 and 273-74 (Univ. Tokyo Press, 1985) . Its cutaneous metabolism and clinical pharmacokinetics is disclosed in de Zeeuw et al., 7 Phar . Res. 638 (1990), Weichers et al., 65 Int. J. Pharm. 77 (1990) . Another testosterone blocker is progesterone, pregn-4-ene-3, 20-dione (commercially available as CORLUTINA™, CORLUVITE™, CYCLOGETS™, GESTIRON™, GESTONE™, LIPOLUTIN™, LUTOCYCLIN M™, PROGESTIN™, CP progesterone powder, etc . . . ) . Progesterone is insoluble in water and soluble n alcohol, acetone, dio^ane, d concentr ted sulfuric acid. It is sparingly soluble in vegetable oils. Its isolation, structure and biological activity is described at length in Bardin et al. (eds.), Progesterone and Progestins (Raven Press, New York 1982) . I prefer to use progesterone as the sole testosterone blocker. Carrier Vehicles The penetration enhancer""and" the vascular toner or testosterone blocker, or both, may be mixed with a carrier vehicle. You can use a variety of vehicles to make my invention. The vehicle is simply a cosmetically safe, medically safe solvent for the active ingredients. The vehicle should not adversely and significantly chemically react with the active ingredients. For example, propylene glycσl, water and isopropyl alcohol may be used as vehicles. These may be used alone or in combination. The vehicle can optionally provide functions in addition to simply dissolving, the active ingredients. For example, one can use a moisturizing vehicle, or a vehicle containing sunscreen. For a moisturizing or moisture retaining vehicle, one can use a vehicle made from a combination of (ranked in order of quantity used) wa e * mineral oil, petrolatum, lanolin, sorbitol solution, stearic acid, lanolin alcohol, cetyl alcohol, glyceryl stearate / PEG-100 stearate, triethanolamine, dimethicone, propylene glycol, tri(PPG-3 myristyl ether) citrate, disodium EDTA, methylparaben, ethylparaben, propylparaben, fragrance, xanthan gum, butylparaben, and methyldibromo glutaronitrile. It may be desirable to use a vehicle containing one or more sunscreens. This is because my preparations are used on the tops of balding scalps. Balding scalps are often largely unprotected from sun damage, as the user may not wear headgear and the balding scalp lacks the sun shielding dense hair layer present on a healthy scalp. Adding sunscreen thus can protect the scalp from possible sun damage. Sunscreens, and vehicles containing sunscreen compounds, are widely known in the art. See, e.g. , United States Letter Patent No. 4,522,807. Other cosmetic vehicles are widely known in the art. I prefer to use VEHICLE/N™ as the vehicle. I prefer to use VEHICLE/N (TM) because it has a cosmetically attractive "feel" to the user. Vehicle/N (TM) is commercially available from the Neutrogena Dermatologies division of Johnson & Johnson, Inc., New Brunswick, New Jersey. It is currently available in two formulations, regular and mild. They are both versatile liquid vehicles for extemporaneous compounding of topical drugs. Both formulations solublize selected dermatological agents and provide astringent and drying actions. The VEHICLE/N (TM) ingredients are SD alcohol 40 (45%), purified water (<45%) , laureth-4 (>4%) , isopropyl alcohol (4%) and propylene glycol (<4%) . The VEHICLE/N (TM) mild ingredients are purified water '(>37.5%), SD alcohol-40 (37.5%), isopropyl alcohol (5%) and laureth-4 (<5%) . To compound with VEHICLE/N, add the appropriate quantity of active ingredient to yield the intended concentration. VEHICLE/N (TM) is available as 50 mL of vehicle in a plastic bottle with applicator top. The bottle is filled only to 3/4 capacity, to ensure proper mixing. For 50 L of VEHICLE/N, use the following amounts: Desired 0.1% 0.2% 0.5% , 1.0% Concentration Bulk Active 50 g 100 g 250 mg 500 mg Tablets lx250mg 4x150 mg 1.2% soln Desired 2.0% - 3.0% 4.0% 5.0% Concentration Bulk Active l.O gm 1.5 gm 2.0 g 2.5 gm For fastest dissolution, when tablets are used, crush them to a powder and then add the powder to the vehicle. When capsules are used, add the capsule contents only to the vehicle, and discard the capsule shell. Shake the mixture gently. Most capsule contents and bulk active ingredients will dissolve within minutes, though some may take longer. VEHICLE/N™ is available in a bottle with an APPLIDERM (TM) applicator top. The APPLIDERM (TM) applicator unit automatically filters the compounded mixture and provides a convenient, spill-proof, self-contained unit for topical application. To use the APPLIDERM (TM) applicator unit, push the applicator firmly into the bottle using the white cap as a holder. Screw the cap all the way down to seat the applicator. Shake well. If tablets are dissolved in the vehicle, then the user should be instructed to allow the solution to stand overnight and to shake vigorously before the first use. VEHICLE/N (TM) should not be used near fire or open flame due to alcohol content. Both VEHICLE/N (TM) and VEHICLE/N (TM) mild contain substantial alcohol and are not suitable for use in acute dermatoses. Stinging may be noted if used on irritated or abraded skin. Avoid contact with eyes or eyelids. If the product accidentally comes in contact with eyes, rinse thoroughly with water and contact physician. Keep out of reach of children. VEHICLE/N (TM) . and VEHICLE/N (TM) mild are contraindicated in persons who have shown hypersensitivity to any of the listed ingredients. Preferred Formulations Given a constant amount of testosterone blocker or vascular toner, I have found that lower concentrations of penetration enhancer can decrease the efficacy of the final formulation, while higher concentrations of penetration enhancer increase the risk of adverse side effects due to systemic penetration of the other active ingredient (s) . Similarly, you may use different testosterone blockers for the same effect, and may use more or less- of it. Using more testosterone blocker allows one to use relatively less penetration enhancer, or a weaker enhancer. Titration of the two components against one another is a conventional technique well known in the art of pharmaceutical and cosmetics formulation. Such techniques are already used to titrate formulations for the wide variety of trans-dermal drugs and cosmetics currently available. For example, in a four ounce quantity of liquid containing 5 drops of trimethyl acetate, I prefer to use one percent (by volume) of soluble progesterone (U.S.P.). A preferred formulation is: The following preparation is acceptable, and within the scope of the claims, but I do not prefer it: Alternatively, an ethyl alcohol - water - propylene glycol solution may be used as the diluents and vehicle. For 100 mL of this formulation, use: ethyl alcohol 95% 75.5 cc purified water 18.5 cc propylene glycol 6.0 cc progesterone 1.5 gm minoxidil 2.0 - 5.0 gm methyl acetate 5.0 gtts These are my preferred formulations. These may be varied as desired, but it is necessary to watch for unwanted side effects possibly due to unwanted systemic penetration of the active ingredient (s) . For example, minoxidil is pharmaceutically and cosmetically effective topically at anywhere from about 0.01 grams to about 50 grams per four ounces, depending on the frequency of topical administration. Testosterone blockers are also pharmaceutically and cosmetically effective topically at anywhere from about 0.01 grams to about- 50 grams per four ounces, depending on the frequency of topical administration. With the higher concentrations, however, increasing the amount of penetration enhancer creates a greater risk of adverse side effects. Summary I have discussed several different specific formulas. I have found these most useful. One can, however, vary the constituents to achieve the same effect without having a substantially different product. For example, one can use a different testosterone blocker, or a weaker penetration enhancer in a higher concentration. Thus, the legal scope of my patent is not limited to the specific examples I discuss herein; rather, the legal coverage of this patent is defined by the appended claims and their equivalents .

Claims: CLAIMS 1. A composition of matter intended for topical use in preventing or treating alopecia, or maintaining healthy hair, said composition of matter, comprising: a) an active compound selected from the group consisting .of: a pharmaceutically or cosmetically effective topical amount of a testosterone blocker and minoxidil, and b) a penetration enhancer, said penetration enhancer present in a concentration sufficient to aid said active compound in penetrating the skin surface to a depth of approximately the depth of hair bulbs . 2. The composition of claim 1, wherein said active compound comprises a testosterone blocker. 3. The composition of claim 1, wherein said active compound comprises minoxidil. 4. The composition of claim 3, further comprising a testosterone blocker. 5. The composition of claim 4, wherein the ratio of penetration enhancer to testosterone blocker to minoxidil in the composition is approximately 5 drops : 0.5 grams : 1 gram. 6. The composition of claim 4, wherein said penetration enhancer is trimethyl acetate and wherein said testosterone blocker is progesterone. 7. The composition of claim 5, wherein said testosterone blocker is present in a concentration of 0.5 grams per 4 ounces of finished liquid. 8. The composition of claim 4, labeled for topical cosmetic use in maintaining normal, healthy hair. 9. The composition of claim 4, labeled for topical pharmaceutical use in preventing or treating a disease. 10. The composition of claim 9, wherein said disease comprises alopecia. 11. The composition of claim 4, further comprising a sunscreen in an amount effective to screen radiation. 12. A for preventing or treating alopecia, or maintaining healthy hair, said method comprising: a) Topically administering an active compound selected from the group consisting of: a pharmaceutically or cosmetically effective topical amount of a testosterone blocker and minoxidil, together with b) a penetration enhancer, said penetration enhancer present in a concentration sufficient to aid said active compound in penetrating the skin surface to a depth of approximately the depth of hair bulbs. 13. The -method of claim 12, wherein said active compound comprises a testosterone blocker. 14. The method of claim 12, wherein said active compound comprises minoxidil. 15. The method of claim 14, wherein said active compound further comprises a testosterone blocker. 16. The method of claim 15, wherein the ratio of penetration enhancer to testosterone blocker to minoxidil in the composition is approximately 5 drops : 0.5 grams : 1 gram. 17. The method of claim 15, wherein said penetration enhancer is trimethyl acetate and wherein said testosterone blocker is progesterone. 18. The method of claim 16, wherein said testosterone blocker is present in a concentration of 0.5 grams per 4 ounces of finished liquid. 19. The method of claim 15, labeled for topical cosmetic use in maintaining normal, healthy hair. 20. The method of claim 15, labeled for topical pharmaceutical use in preventing or treating a disease. 21. The method of claim 20, wherein said disease comprises alopecia. 2. The method of claim 15, further comprising a sunscreen in an amount effective to screen radiation. AMENDED CLAIMS [received by the International Bureau on 10 January 2002 (10.01.02); original claims 1-22 replaced by amended claims 1-22 (3 pages)] 1. A composition of matter intended for topical use in prβvpnt.i ng or t eating alo pM« r or mnai ntsining healthy hair, said composition of matter comprising: a) an active compound selected from the group consisting of: a pharmaceutically or cosmetically effective topical amount of a 5α-reductase inhibitor and minoxidil, and b) a non-retinύid peueLi.---.iu_i mihaacui, said peπetxaLion enhancer present in a concentration sufficient to aid said active compound in penetrating the skin surface to a depth of approximately the depth of hair hulbs. 2. The composition of claim 1, wherein said active compound comprises a 5o-reductase inhibitor. 3. The composition of claim 1, wherein said active compound comprises minoxidil. 4. The composition of claim 3, further coiiipiisiay Λ Oα- reductase inhibitor. 5. The composition of claim 4, wherein the ratio of 5a- rftduct.nsfi inhibitor tn m ovidil in h composition i <? approximately 0.5 grams : 1 gram. 6. The composition of claim 4, wherein said penetration enhancer is trimethyl acetate and wherein said 5a- reductase inhibitor is progesterone. 7. The com osition ul L-leii.ii 5, wl.ei.t-i-- -sdid 5tt--.t_duc L---jfc- inhibitor is present in a concentration of 0.5 grams per 4 ounces of finished liquid. R. An artir.lp f manu c ure comprising the composition of claim 4, labeled for topical cosmetic use in maintaining normal, healthy hair. 9. An article of manufacture comprising the composition of claim 4, labeled for topical pharmaceutical use in preventing or treating a disease. 10. The article of manufacture of claim 9, wherein said disease comprises alopecia. 11 ■ The composition of claim 4, further comprising a sunscreen in an amount effective to screen radiation . 12. A method for preventing or treating alopecia, or maintaining healthy hair, said method comprising: a) Topically administering an active compound selected from the group consisting of: a pharmaceutically or cosmetically effective topical amount of a 5 -reductase inhibitor and minoxidil, together with h) Λ nnn-rpf nniri ppnpf a ion enhanr.-er, said penetration enhancer present in a concentration sufficient to aid said active compound in penetrating the skin surface to a depth of approximately the depth of hair bulbs. 13. The method of claim 12, wherein said active compound COΛi -.ist-iS Λ Dα-itsduuldse inhiblLυx. 14. The method of claim 12, wherein said active compound comprises minoxidil. 15. The method of claim 14, wherein said active compound further comprises a 5«-reductase inhibitor. 16. The method of claim 15, wherein the ratio of 5α- reductase inhibitor to minoxidil in the composition is approximately 0.5 grams J 1 gram. 17. The method of claim 15, wherein said penetration enhancer is trimethyl acetate and wherein said 5α- reductase inhibitor is progesterone. 18. The method of claim 16, wherein said δo-reductaee inhibitor is present in a concentration of 0.5 grams per 4 ounces of finished liquid. 19. The method of claim 15, labeled for topical cosmetic use in maintaining normal, healthy hair. 20. The method of claim 15, labeled for topical pharmaceutical use in preventing or treating a disease. 21. The method of claim ?0, wherein said disease comprises alopecia. 22. The method of claim 15, further comprising a sunscreen in an amount effective to screen radiation. STATEMENT UNDER ARTICLE 19 (1) Claims 6 and 17 stand allowable in the United States counterpart application. Claims 5 and 16 are amended to delete the claim term "drop," which term the Examiner in the United States counterpart has argued is vague. Claims 8-10 are amended to clarity that they require a label for a specific class of use. Claims U 2, 4, 5, 7, 15, 16, 18 are amended to replace the term "testosterone blocker" with "5α-reductase inhibitor." In the United States counterpart the Examiner says inhibitors ot ' 5-reductase are testosterone blockers (not testosterone inhibitors). The Examiner relies on SPECIFICATION page 6. That page, however, says testosterone inhibitor, not testosterone blocker. The term "testosterone blocker" has been replaced throughout the claims with the term "3α-reductase Inhibitor," which term is supported at the page cited by the Examiner. The claims are amended to exclude from the term "penetration enhancer" Bazzaπo's retinoid compounds. Box No. VIII (v) DECJ ATION: NON-PREJUDICIAL DISCLOSURES OR EPTIONS TO LACK OF NOVELTY The declaration must conform to the standardizedwordingprovidedfor in Section 215; see Notes to Boxes Nos. VIII, VIII (i) to (v) (in general) and the speβiflύ Notes to Box No, VIII (\>)> If this Box is not used, this sheet should not be included in the request, Declaration as to non-prejudicial disclosures or exceptions to lack of novelty (Rules 4.17(v) and 5\bis. l(a)(v)): ~ za. Dt ciceuπz, I I This declaration is continued on the following sheet, "Continuation of Box No. VIII (v)". Form PCT/RO/101 (declaration sheet (v)) (March 2001) See Notes to the request form 1 Unique cHalion designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (W1PO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate βymbo aa Indleated on ( he document uπd-r WIPO Standard ST, 16 if possible. * Applicant is to place a check mark here English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete.. Time wilt vary depending upon the needs of the individual case. Any comments on the amount of lime you are required to complete thb form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEBS OR COMPIBTED TOHM9 TO THIS ADDRESS, SEND TO: Aαiotαnt Commisi-oπβr for Patents, Washington, DC 20231.

Inventors: KNOWLES W ROY, KNOWLES, W., ROY
Applicants: KNOWLES W ROY, KNOWLES, W., ROY
Application year: 2001
Main classification: A61K31
IPC codes: A61K8, A61K31, A61K45, A61K47, A61P17, A61P43, A61Q5, A61Q7